Trial Profile

A Clinical Study to Assess the Safety and Efficacy of Sutacimig in Participants With Congenital Factor VII Deficiency

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sutacimig (Primary)
Indications Factor VII deficiency
Focus Adverse reactions
Sponsors Hemab

Most Recent Events

12 Jul 2026 According to a Hemab Therapeutics media release, data from this study presented at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France.
12 Jul 2026 Results presented in the Hemab Therapeutics media release.
21 May 2026 According to a Hemab media release, Company expects to report data from the trial in late 2026 or early 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com